Bandingkan Harga & Kinerja Energi Mega Persada Tbk. (ENRG) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Energi Mega Persada Tbk. dan Organon Pharma Indonesia Tbk.: Energi Mega Persada Tbk. diperdagangkan di Rp1.460 (kapitalisasi pasar 38,78 T, volume 24 jam 147,39 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Energi Mega Persada Tbk. jauh lebih besar — sekitar 371,5× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| ENRG | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 38,78 T | 104,4 M |
Volume | 147,39 jt | — |
Lot | 1,47 jt | — |
Perputaran | 221 M | — |
Harga Rata-rata | 1.499,46 | — |
Nilai Transaksi | 221 M | — |
Harga Ekuilibrium Indikatif | 1.460 | — |
Volume Ekuilibrium Indikatif | 23,03 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Energi Mega Persada Tbk.
PT Energi Mega Persada (Company) was established base on notarial deed No. 16 of H. Rakhmat Syamsul Rizal SH, dated Oct 16, 2001. The deed of establishment was approved by the Ministry of Justice in its decision letter No. C2-14507.HT.01.01.Th.2001 dated Nov 29, 2001. The Company’s articles of association has been amended several times, most recently by notarial deed No. 40 of Lena Magdalena S.H., dated Mar 30, 2004, concerning among others, the change in the Company’s name, increasing in capital paid up and public offering of stock.
Selengkapnya di halaman ENRG →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
